3 results
Approved WMOCompleted
To determine the conversion rate of PR to CR (i.e. PET negativity) after a single dose of 90Y-ibritumomab tiuxetan (a dose of 14.8 MBq/kg or 0.4 mCi/kg, max 1184 MBq or 32mCi) in patients with grade 1-3a, stage II, III or IV follicular lymphoma with…
Approved WMOCompleted
The primary objective of this study is to determine the effects of aliskiren, as compared to ramipril, on renal hemodynamics in overweight/obese and hypertensive patients.
Approved WMOPending
Primary Objective: To evaluate the *Triple Aim* performance of Care Pathway Technology for RA: - Evaluate and compare predefined RA health outcomes; Disease activity measured by DAS 28 joint score at baseline, month 12; RAPID3, HAQ-DI at baseline…